Alumis (NASDAQ: ALMS) is up about 9.2% to $10.34 on roughly 6.25 million shares, as reported by StockAnalysis at 12:39 PM ET. That's the day after it closed down 56.6% at $9.47 on Tuesday — from $21.81 on Monday, per RTTNews. Tuesday's volume was 28.4 million shares. So the market has paid back roughly a sixth of what it took away, and the reason is unusually specific.

What happened Tuesday

At 7:30 AM ET on September 1, Alumis released topline data from LUMUS, a Phase 2b trial of envudeucitinib — an oral TYK2 inhibitor — in moderate-to-severe systemic lupus. The trial enrolled 408 patients across three dose arms plus placebo. It missed its primary endpoint: BICLA response at Week 48. BICLA is a composite score doctors use to judge whether a lupus patient's disease activity actually improved across organ systems, so missing it means the drug didn't beat placebo on the headline measure.

Why it's bouncing today

Three sell-side notes landed today, and they all argue the same thing — the selloff overshot:

• Wells Fargo cut its target from $51 to $25 but kept Overweight. Analyst Derek Archila cut the lupus probability of success from 75% to 35% — and still carries lupus at about $6 a share plus psoriasis at about $13 a share. That's $19 of modelled value against a $10 stock.
• Morgan Stanley cut its target from $39 to $29, also keeping Overweight, and went further: it removed lupus from the model entirely. That indication had been carried at roughly $500 million of risk-adjusted 2040 sales — a 40% probability against $2.5 billion in total.
• HC Wainwright did the opposite of a downgrade: it moved Alumis from Neutral to Buy, while trimming its target from $25 to $15.

Two firms cut their numbers and still said buy. One got more positive because the price fell. That combination is what a 9% bounce looks like.

The part the headline hides: IFNGS

Lupus patients split into two groups — those with a high "interferon gene signature" (IFNGS-high) and those without. Envudeucitinib blocks TYK2, an enzyme that sits inside the interferon signalling pathway, so it should only really work on the IFNGS-high group. In that prespecified subgroup, the drug did deliver, on BICLA and on the secondary measures (CLASI-50, SRI-4, LLDAS). Alumis says IFNGS-high patients are the majority of real-world moderate-to-severe lupus, but were under-represented in LUMUS, diluting the overall result.

That's the company arguing it has a population problem, not a molecule problem. It's also the argument every failed trial makes — which is precisely why the market handed back a sixth of the loss and not the whole thing. Alumis says it will approach regulators about a Phase 3 run only in IFNGS-high patients.

The business

Alumis is clinical-stage with no product revenue, and one molecule carries most of the value:

• Plaque psoriasis — the lead program, and the furthest along. Phase 3 ONWARD1 showed PASI 90 of 68.0% and PASI 100 of 41.0% at Week 24. NDA submission is guided for Q4 2026. This program was not in Tuesday's trial.
• Lupus (SLE) — the one that just missed.
• A-005, a brain-penetrant TYK2 for neuroinflammation; a Phase 2 biomarker trial in Parkinson's is targeted for H1 2027.
• Lonigutamab, on which Alumis booked a $41.8 million impairment inside its $142.2 million Q2 2026 net loss.

Is it expensive?

There is no P/E — Alumis lost $438.96 million over the trailing twelve months, so the ratio doesn't exist. You value it off the balance sheet instead. Market cap is $1.34 billion, cash and short-term investments $502.29 million, total debt $36.4 million, giving an enterprise value of about $872 million. Price-to-book is 2.69 against book value of $3.52 a share (all StockAnalysis). Strip out the cash and the market is paying roughly $870 million for the entire pipeline.

For scale, use the drug it would compete with. Bristol Myers Squibb's Sotyktu — the approved oral TYK2 — did $291 million in worldwide 2025 revenue, up 19% (BMS Q4 2025 release). That's the shape of this market: a useful, growing, few-hundred-million-dollar drug several years post-launch, not a blockbuster. Against that, an $872 million enterprise value is neither a bargain nor obviously silly — it's a wager that the psoriasis NDA lands and the label reads better than Sotyktu's.

Who else this touches

• Bristol Myers Squibb — Sotyktu is the incumbent oral TYK2; an Alumis filing with those PASI numbers is a direct competitive read.
• Johnson & Johnson — Morgan Stanley named Icotyde as the other label envudeucitinib gets measured against.
• Anyone else running TYK2 in lupus — LUMUS is data on the mechanism in that disease, not just on this company. The IFNGS-high signal is a hint about how to enrol the next trial.

The risk that flips it

Roughly $13 of Wells Fargo's $25 sits in psoriasis, so the Q4 2026 NDA is the whole story now. Alumis said its cash funds operations into Q4 2027. A filing delay or a refuse-to-file wouldn't only push out revenue — it would push the company toward raising money against a $10 share price instead of a $22 one, which is a very different amount of dilution. The second risk is regulatory: if the FDA won't accept a subgroup-only pivotal design in IFNGS-high patients, the ~$6 a share Wells Fargo still carries for lupus goes too.

As of 12:39 PM ET, September 2, 2026. Sources: StockAnalysis, Alumis LUMUS topline release, Investing.com (Wells Fargo), Investing.com (Morgan Stanley), Alumis Q2 2026 results, BMS Q4 2025 release, RTTNews. For discussion and education only — not investment advice. Verify before acting.